Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2016

01-10-2016 | Original Article

Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis

Authors: Kiyoki Kitagawa, Kengo Furuichi, Akihiro Sagara, Yasuyuki Shinozaki, Shinji Kitajima, Tadashi Toyama, Akinori Hara, Yasunori Iwata, Norihiko Sakai, Miho Shimizu, Shuichi Kaneko, Takashi Wada, Kanazawa Study Group for Renal Diseases and Hypertension

Published in: Clinical and Experimental Nephrology | Issue 5/2016

Login to get access

Abstract

Background

The prevention of relapse and infection complications during remission maintenance therapy is required to improve the prognosis of patients with microscopic polyangiitis (MPA) showing rapidly progressive glomerulonephritis (RPGN). The clinicopathological characteristics of patients with ANCA-positive MPA were examined to determine the risk factors for relapse or infectious complications after remission induction therapy.

Patients and methods

The study population consisted of 52 patients diagnosed as ANCA-positive MPA showing RPGN from 2002 to 2012, after publication of the Japanese guideline for RPGN. The clinicopathological findings were examined between the presence and absence of relapse or infectious complications.

Results

The value of vasculitis damage index (VDI) was high for the relapse group and VDI value was identified as the leading factor associated with relapse [hazard ratio (HR) 3.36, 95 % confidence interval (CI) 1.58–7.12, P < 0.01]. On the other hand, the values of Birmingham Vasculitis Activity Score, clinical grade category of RPGN at diagnosis, and VDI at remission were high in the infectious group. Furthermore, clinical grade category of RPGN was the leading factor associated with infectious complications (HR 5.30, 95 % CI 1.41–19.9, P = 0.01).

Conclusion

The disease activity at diagnosis and severity of organ damage at remission were associated with relapse and infectious complications during remission maintenance therapy and infectious complication affected kidney survival and all-cause mortality in patients with ANCA-positive MPA exhibiting RPGN.
Literature
1.
go back to reference Churg J, Bernstein J, Glassock RJ. Classification of glomerular disease. In: Churg J, Bernstein J, Glassock RJ editors. Renal disease classification and atlas of glomerular diseases, 2nd ed. New York; 1995. p. 11. Churg J, Bernstein J, Glassock RJ. Classification of glomerular disease. In: Churg J, Bernstein J, Glassock RJ editors. Renal disease classification and atlas of glomerular diseases, 2nd ed. New York; 1995. p. 11.
2.
go back to reference Kitagawa K, Furuichi K, Shinozaki Y, Toyama T, Kitajima S, Hara A, et al. Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol. 2013;17:858–65.CrossRefPubMed Kitagawa K, Furuichi K, Shinozaki Y, Toyama T, Kitajima S, Hara A, et al. Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol. 2013;17:858–65.CrossRefPubMed
3.
go back to reference Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed
4.
go back to reference Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166–73.CrossRef Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166–73.CrossRef
5.
go back to reference Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96.CrossRefPubMed Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96.CrossRefPubMed
6.
go back to reference Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283–92.PubMed Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283–92.PubMed
7.
go back to reference Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371–80.CrossRefPubMed Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371–80.CrossRefPubMed
8.
go back to reference Wada T, Hara A, Arimura Y, Sada K-E, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.CrossRefPubMed Wada T, Hara A, Arimura Y, Sada K-E, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.CrossRefPubMed
9.
go back to reference Kitajima S, Furuichi K, Sakai N, Sagara A, Shinozaki Y, Toyama T, et al. Relapse and its remission in Japanese patients with idiopathic membranous nephropathy. Clin Exp Nephrol. 2015;19:278–83.CrossRefPubMed Kitajima S, Furuichi K, Sakai N, Sagara A, Shinozaki Y, Toyama T, et al. Relapse and its remission in Japanese patients with idiopathic membranous nephropathy. Clin Exp Nephrol. 2015;19:278–83.CrossRefPubMed
10.
go back to reference Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.CrossRefPubMed Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.CrossRefPubMed
11.
go back to reference Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:v1615–6.CrossRef Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:v1615–6.CrossRef
12.
go back to reference Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394–404.CrossRefPubMed Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394–404.CrossRefPubMed
13.
go back to reference Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102:c35–42.CrossRefPubMed Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102:c35–42.CrossRefPubMed
14.
go back to reference Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.CrossRefPubMed Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.CrossRefPubMed
15.
go back to reference Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.CrossRefPubMed Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.CrossRefPubMed
16.
go back to reference Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–13.CrossRefPubMed Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–13.CrossRefPubMed
17.
go back to reference Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, Kato M, Murakami K, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients. Ther Apher Dial. 2006;10:412–8.CrossRefPubMed Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, Kato M, Murakami K, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients. Ther Apher Dial. 2006;10:412–8.CrossRefPubMed
Metadata
Title
Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis
Authors
Kiyoki Kitagawa
Kengo Furuichi
Akihiro Sagara
Yasuyuki Shinozaki
Shinji Kitajima
Tadashi Toyama
Akinori Hara
Yasunori Iwata
Norihiko Sakai
Miho Shimizu
Shuichi Kaneko
Takashi Wada
Kanazawa Study Group for Renal Diseases and Hypertension
Publication date
01-10-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1199-7

Other articles of this Issue 5/2016

Clinical and Experimental Nephrology 5/2016 Go to the issue